XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. Understanding the market dynamics of diabetes treatments becomes crucial for professionals across these industries. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

JUNE 5, 2023

Ozempic and Wegovy, which contain the active ingredient semaglutide, were approved by the US Food and Drug Administration (FDA). Ozempic was approved for the management of type 2 diabetes mellitus in adults in addition to a reduced-calorie diet and exercise. The approved drugs contain the base form of semaglutide.

FDA Approval 98

FDA Approval Containment Drugs Pharmacy 98

XTalks

NOVEMBER 9, 2022

Since Mounjaro’s May US Food and Drug Administration (FDA) approval, sales of the drug have skyrocketed beyond initial expectations owing to patient demand and a temporary shortage of Novo’s Ozempic. Since then, several more GLP-1 agonists have been approved by the FDA. And the demand won’t be easing anytime soon.

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

AUGUST 2, 2023

Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. It contains the antiviral medications nirmatrelvir and ritonavir. In addition, the FDA approved Pfizer’s pneumococcal 20-valent conjugate vaccine, Prevnar 20, for the first time in June 2021.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

APRIL 29, 2022

Tirzepatide is a novel investigational obesity treatment that contains mimetics of two hormones that are involved in regulating appetite in a single peptide: a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist and a GLP-1 (glucagon-like peptide-1) receptor agonist.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

AUGUST 17, 2020

In 2017, the US FDA approved a CAR-T cell treatment for young adults and children with B-cell ALL. The first class of Immuno-STAT molecules from Cue Biopharma contain an epitope-targeted peptide-HLA complex (signal 1) and a T cell activator i.e. molecules of IL-2 (signal 2) on an Fc antibody backbone. Image from Cue Biopharma.

Protein 98

Protein Engineer Immune Response In-Vivo 98